| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 07/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Exhibit 99.1 ImmuCell Announces Change in Timing of Anticipated FDA Submission PORTLAND, Maine, June 28, 2023 -- ImmuCell Corporation , a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule. “Although we had planned to make our next FDA submission during the second quarter of this year, we have decided to add one additional month to the projected regulatory development process for Re-Tain,” commented Michael F. Brigham, President and CEO of ImmuCell. “The CMC Technical Section is ready for submission at this time, but we are going to use this extra time to optimize our readiness for the related ..." |
|
| 05/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/05/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
4
| Tomsche David Scott (Director) has filed a Form 4 on IMMUCELL CORP /DE/|
Txns:
| Disposed/sold 400 shares
@ $5.2, valued at
$2.1k
Disposed/sold 300 shares
@ $5.24, valued at
$1.6k
Disposed/sold 200 shares
@ $5.25, valued at
$1.1k
Disposed/sold 900 shares
@ $5.37, valued at
$4.8k
Disposed/sold 80 shares
@ $5.34, valued at
$427.2
Disposed/sold 3 shares
@ $5.24, valued at
$15.7
Disposed/sold 7 shares
@ $5.24, valued at
$36.7
Disposed/sold 10 shares
@ $5.23, valued at
$52.3
Disposed/sold 100 shares
@ $5.24, valued at
$524
Disposed/sold 71 shares
@ $5.5, valued at
$390.5
Disposed/sold 309 shares
@ $5.5, valued at
$1.7k
|
|
| 02/28/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/24/2023 |
4
| Wainman Paul R (Director) has filed a Form 4 on IMMUCELL CORP /DE/|
Txns:
| Granted 10,000 options to buy
@ $6.52, valued at
$65.2k
|
|
| 01/24/2023 |
4
| Tomsche David Scott (Director) has filed a Form 4 on IMMUCELL CORP /DE/|
Txns:
| Granted 10,000 options to buy
@ $6.52, valued at
$65.2k
|
|
| 01/24/2023 |
4
| Rosgen Steven T. (Director) has filed a Form 4 on IMMUCELL CORP /DE/|
Txns:
| Granted 10,000 options to buy
@ $6.52, valued at
$65.2k
|
|
| 01/24/2023 |
4
| Cunningham David (Director) has filed a Form 4 on IMMUCELL CORP /DE/|
Txns:
| Granted 10,000 options to buy
@ $6.52, valued at
$65.2k
|
|
| 01/24/2023 |
4
| Basse Gloria F (Director) has filed a Form 4 on IMMUCELL CORP /DE/|
Txns:
| Granted 10,000 options to buy
@ $6.52, valued at
$65.2k
|
|
| 01/24/2023 |
3
| Basse Gloria F (Director) has filed a Form 3 on IMMUCELL CORP /DE/ |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/21/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/21/2022 |
10-Q/A
| Quarterly Report for the period ended June 30, 2022 [amend] |
| 11/21/2022 |
10-Q/A
| Quarterly Report for the period ended March 31, 2022 [amend] |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 10/05/2022 |
8-K
| Quarterly results |
| 09/12/2022 |
4
| Tomsche David Scott (Director) has filed a Form 4 on IMMUCELL CORP /DE/|
Txns:
| Disposed/sold 306 shares
@ $7.68, valued at
$2.4k
Disposed/sold 329 shares
@ $7.71, valued at
$2.5k
Disposed/sold 5 shares
@ $7.72, valued at
$38.6
Disposed/sold 5 shares
@ $7.7, valued at
$38.5
Disposed/sold 260 shares
@ $7.69, valued at
$2k
Disposed/sold 1 shares
@ $7.62, valued at
$7.6
Disposed/sold 647 shares
@ $7.76, valued at
$5k
Disposed/sold 33 shares
@ $7.8, valued at
$257.4
Disposed/sold 20 shares
@ $7.7, valued at
$154
Disposed/sold 606 shares
@ $7.75, valued at
$4.7k
Disposed/sold 195 shares
@ $7.8, valued at
$1.5k
|
|
| 08/17/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|